Pharmacotherapy of Peptic Ulcer
Pharmacotherapy of Peptic Ulcer
Drugs that reduce gastric acidity, protect the mucosa and eradicate H. pylori
Introduction
Important Causes
- Helicobacter pylori: A major cause of chronic gastritis and peptic ulcer disease.
- NSAIDs: Reduce protective prostaglandin synthesis and weaken the gastric mucosal barrier.
- Excessive acid secretion and other factors may contribute to ulcer formation.
Protective Mechanisms
- Mucus and bicarbonate form a protective surface barrier.
- Prostaglandins support mucus and bicarbonate secretion.
- Good mucosal blood flow helps maintain tissue health.
- Rapid repair and replacement of epithelial cells help heal injury.
Principles of Treatment
- Reduce gastric acid secretion.
- Eradicate H. pylori when infection is confirmed.
- Protect the ulcer surface and promote healing.
- Avoid or minimise ulcer-producing medicines such as NSAIDs when possible.
Drugs that Reduce Acid Secretion
H2-Receptor Blockers
Examples: Famotidine, cimetidine and nizatidine.
- Competitively block histamine H2 receptors on gastric parietal cells.
- Reduce basal and stimulated gastric acid secretion.
- Used in selected cases of peptic ulcer, gastro-oesophageal reflux and acid-related disorders.
Famotidine has fewer drug interactions and lacks the anti-androgenic effects associated with cimetidine.
Proton Pump Inhibitors (PPIs)
Examples: Omeprazole, pantoprazole, esomeprazole, lansoprazole and rabeprazole.
- Inhibit the gastric H+/K+ ATPase enzyme, also called the proton pump.
- Block the final step of acid secretion and produce powerful acid suppression.
- They are commonly taken before meals according to the prescribed preparation and schedule.
Therapeutic Uses of PPIs
- Healing of gastric and duodenal ulcers.
- NSAID-associated ulcers and prevention in selected high-risk patients.
- Gastro-oesophageal reflux disease, especially when oesophagitis is present.
- Zollinger–Ellison syndrome.
- Part of combination treatment for H. pylori infection.
Other Acid-Reducing Drugs
- Anticholinergics: Reduce gastric secretion but are limited by adverse effects such as dry mouth, blurred vision and urinary retention.
- Misoprostol: A prostaglandin analogue that reduces acid secretion and increases mucus and bicarbonate. It can prevent NSAID-induced ulcers but is contraindicated in pregnancy because it can cause uterine contractions.
Antacids
Classification
Adverse Effects
- Magnesium salts: Diarrhoea; use cautiously in renal impairment.
- Aluminium salts: Constipation and, with prolonged use, phosphate depletion.
- Sodium bicarbonate: Belching, sodium retention and metabolic alkalosis.
Why Magnesium and Aluminium Are Combined
- Magnesium acts relatively quickly, while aluminium provides a slower effect.
- Magnesium may cause diarrhoea, whereas aluminium may cause constipation.
- Combining them can balance bowel effects and improve tolerability.
Ulcer Protective Drugs
Sucralfate
- Forms a protective coating over the ulcer surface and acts as a physical barrier against acid and pepsin.
- Adheres preferentially to damaged tissue and supports mucosal protection.
- Usually administered before meals on an empty stomach as prescribed.
- May interfere with absorption of other medicines, so doses should be separated.
Bismuth Compounds
Examples include colloidal bismuth subcitrate and bismuth subsalicylate.
- Coat the ulcer surface and increase mucosal defence.
- Have activity against H. pylori and are used in selected eradication regimens.
- May cause darkening of the tongue and stools.
Carbenoxolone
It promotes mucus production and mucosal healing but is rarely used because of steroid-like adverse effects.
- May cause sodium and water retention, oedema and hypertension.
- May reduce potassium levels.
H. pylori Eradication
H. pylori is a gram-negative bacterium that survives in the stomach and damages the mucosal defence system. Confirmed infection in patients with peptic ulcer disease should be treated.
Drugs Used
- Proton pump inhibitor.
- Amoxicillin.
- Clarithromycin, metronidazole or tetracycline, depending on the selected regimen and local resistance patterns.
- Bismuth may be included in appropriate combination regimens.
Confirmation of Eradication
Successful treatment may be checked with a urea breath test or stool antigen test at the recommended time after therapy. Acid-suppressing medicines may need to be withheld before testing as advised by the clinician.